THC BioMed Intl (CSE: THC) is looking at joining the fight against the pandemic with cannabis. The firm announced today securing a license from an unnamed overseas government to cultivate cannabis for medical and scientific use.
Citing research on the topic, including a published University of Chicago study, the firm intends to work on the potential of cannabidiol to prevent or inhibit SARS-CoV-2 infection–the virus that causes COVID-19. Initial studies show that CBD has the capacity to help prime cells in our body to fight the virus but clinical studies are required to follow through.
The company said it is in “advanced discussions” with the host country and is now seeking amendments or clarification on the granted license related to the planned scientific research.
THC BioMed last traded at $0.075 on the CSE.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.